Dianthus Therapeutics (DNTH) Other financing activities (2018 - 2025)

Dianthus Therapeutics' Other financing activities history runs 8 years deep, the most recent figure standing at $271.7 million for Q3 2025.

• In Q3 2025, Other financing activities rose 91680.07% year-over-year to $271.7 million; the TTM figure through Sep 2025 stood at $272.7 million (up 44320.85% YoY), while the FY2024 annual figure was $1.1 million, up 21700.0% from the prior year.
• Other financing activities for Q3 2025 stood at $271.7 million, up from $568000.0 in the prior quarter.
• The five-year high for Other financing activities was $271.7 million in Q3 2025, with the low at -$49000.0 in Q3 2022.
• The 5-year median for Other financing activities is $296000.0 (2024), against an average of $32.7 million.
• Peak annual rise in Other financing activities reached 91680.07% in 2025, while the deepest fall reached 88.56% in 2025.
• Dianthus Therapeutics' Other financing activities stood at $86.0 million in 2021, then slumped by 100.06% to -$49000.0 in 2022, then surged by 110.2% to $5000.0 in 2023, then surged by 9420.0% to $476000.0 in 2024, then jumped by 56973.32% to $271.7 million in 2025.
• Business Quant data shows DNTH's Other financing activities at $271.7 million in Q3 2025, $568000.0 in Q2 2025, and $31000.0 in Q1 2025.